TG Therapeutics (NASDAQ:TGTX) Releases Earnings Results, Misses Estimates By $0.02 EPS

TG Therapeutics (NASDAQ:TGTX) issued its earnings results on Wednesday. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02), Briefing.com reports. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The firm had revenue of $63.47 million during the quarter, compared to the consensus estimate of $54.60 million. During the same period in the prior year, the company posted ($0.28) EPS. The company’s quarterly revenue was up 713.5% on a year-over-year basis.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock traded up $0.09 during trading hours on Thursday, reaching $15.97. The company’s stock had a trading volume of 3,546,442 shares, compared to its average volume of 4,274,592. The firm has a 50 day moving average price of $15.13 and a 200-day moving average price of $14.33. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18. The stock has a market cap of $2.47 billion, a P/E ratio of 800.40 and a beta of 2.33. TG Therapeutics has a one year low of $6.46 and a one year high of $35.67.

Insider Buying and Selling at TG Therapeutics

In other news, Director Laurence N. Charney sold 22,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the transaction, the director now directly owns 215,229 shares of the company’s stock, valued at approximately $3,437,207.13. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 9.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on TGTX shares. The Goldman Sachs Group increased their target price on TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of TG Therapeutics in a report on Thursday, April 18th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $25.00 target price on shares of TG Therapeutics in a research note on Thursday, April 18th. StockNews.com downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 24th. Finally, B. Riley lifted their target price on TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Monday, February 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.17.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.